ProtoKinetix (PKTX) 10-Q 31 Oct 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Oct. 26, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-32917
Entity Registrant Name	PROTOKINETIX, INCORPORATED
Entity Central Index Key	0001128189
Entity Tax Identification Number	94-3355026
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	412 Mulberry St.
Entity Address, City or Town	Marietta
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	45750
City Area Code	740
Local Phone Number	434-5041
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		314,330,151

BALANCE SHEETS (Unaudited)

BALANCE SHEETS (Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current Assets
Cash	$ 43,712	$ 57,568
Prepaid expenses (Note 3)	1,050	25,995
Total current assets	44,762	83,563
Intangible assets (Note 4)	434,977	362,671
Total assets	479,739	446,234
Current Liabilities
Accounts payable and accrued liabilities	105,033	93,268
Total liabilities	105,033	93,268
Stockholders’ Equity
Common stock, $0.0000053 par value; 500,000,000 common shares authorized; 314,330,151 and 297,393,485 shares issued and outstanding as at September 30, 2022 and December 31, 2021 respectively (Note 7)	1,681	1,591
Additional paid-in capital	47,237,847	45,892,545
Accumulated deficit	(46,864,822)	(45,541,170)
Total stockholders’ equity	374,706	352,966
Total liabilities and stockholders’ equity	$ 479,739	$ 446,234

BALANCE SHEETS (Unaudited) (Par

BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.0000053	$ 0.0000053
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	314,330,151	297,393,485
Common Stock, Shares, Outstanding	314,330,151	297,393,485

STATEMENTS OF OPERATIONS (Unaud

STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
EXPENSES
Amortization – intangible assets (Note 4)	$ 750	$ 750	$ 2,250	$ 2,250
General and administrative	31,690	34,346	146,227	278,308
Professional fees	33,122	27,397	121,015	89,479
Research and development	160,994	100,888	426,968	250,419
Share-based compensation (Notes 5 and 8)	143,486	1,238,638	627,192	1,314,700
Operating Income (Expenses)	(370,042)	(1,402,018)	(1,323,652)	(1,935,156)
Net loss for the period	$ (370,042)	$ (1,402,018)	$ (1,323,652)	$ (1,935,156)
Net loss per common share (basic and diluted)	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.01)
Weighted average number of common shares outstanding (basic and diluted)	290,989,603	290,414,046	299,244,493	287,443,326

STATEMENT OF STOCKHOLDERS' EQUI

STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 1,531	$ 43,615,323	$ (43,192,633)	$ 424,221
Beginning balance, Shares at Dec. 31, 2020	285,955,071
Issuance of common stock pursuant to private placement offering	$ 28	414,973		415,001
Issuance of common stock pursuant to private placement offering, Shares	5,168,572
Issuance of common stock pursuant to warrant exercise	$ 15	259,985		260,000
Issuance of common stock pursuant to warrant exercise, Shares	3,000,000
Issuance of common stock pursuant to cashless option exercise	$ 3	(3)
Issuance of common stock pursuant to cashless option exercise, Shares	555,556
Fair value of share-based compensation		1,314,700		1,314,700
Net loss for the period			(1,935,156)	(1,935,156)
Ending balance, value at Sep. 30, 2021	$ 1,577	45,604,978	(45,127,789)	478,766
Ending balance, Shares at Sep. 30, 2021	294,679,199
Beginning balance, value at Jun. 30, 2021	$ 1,563	44,128,354	(43,729,442)	400,475
Beginning balance, Shares at Jun. 30, 2021	292,039,199
Issuance of common stock pursuant to private placement offering	$ 9	167,991		168,000
Issuance of common stock pursuant to private placement offering, Shares	1,640,000
Issuance of common stock pursuant to warrant exercise	$ 5	69,995		70,000
Issuance of common stock pursuant to warrant exercise, Shares	1,000,000
Issuance of common stock pursuant to cashless option exercise
Fair value of share-based compensation		1,238,638		1,238,638
Net loss for the period			(1,402,018)	(1,402,018)
Ending balance, value at Sep. 30, 2021	$ 1,577	45,604,978	(45,127,789)	478,766
Ending balance, Shares at Sep. 30, 2021	294,679,199
Beginning balance, value at Dec. 31, 2021	$ 1,591	45,892,545	(45,541,170)	352,966
Beginning balance, Shares at Dec. 31, 2021	297,393,485
Issuance of common stock pursuant to private placement offering	$ 90	718,110		718,200
Issuance of common stock pursuant to private placement offering, Shares	16,936,666
Fair value of share-based compensation		627,192		627,192
Net loss for the period			(1,323,652)	(1,323,652)
Ending balance, value at Sep. 30, 2022	$ 1,681	47,237,847	(46,864,822)	374,706
Ending balance, Shares at Sep. 30, 2022	314,330,151
Beginning balance, value at Jun. 30, 2022	$ 1,641	46,869,401	(46,494,780)	376,262
Beginning balance, Shares at Jun. 30, 2022	306,830,151
Issuance of common stock pursuant to private placement offering	$ 40	224,960		225,000
Issuance of common stock pursuant to private placement offering, Shares	7,500,000
Fair value of share-based compensation		143,486		143,486
Net loss for the period			(370,042)	(370,042)
Ending balance, value at Sep. 30, 2022	$ 1,681	$ 47,237,847	$ (46,864,822)	$ 374,706
Ending balance, Shares at Sep. 30, 2022	314,330,151

STATEMENTS OF CASH FLOWS (Unaud

STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS USED IN OPERATING ACTIVITIES
Net loss for the period	$ (1,323,652)	$ (1,935,156)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization – intangible assets	2,250	2,250
Fair value of share-based compensation	627,192	1,314,700
Changes in operating assets and liabilities:
Prepaid expenses and deposits	24,945
Accounts payable and accrued liabilities	11,765	(37,960)
Net cash used in operating activities	(657,500)	(656,166)
CASH FLOWS USED IN INVESTING ACTIVITIES
Purchase of intangible assets	(74,556)	(66,981)
Net cash used in investing activities	(74,556)	(66,981)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock for cash	718,200	675,001
Net cash from financing activities	718,200	675,001
Net change in cash	(13,856)	(48,146)
Cash, beginning of period	57,568	193,445
Cash, end of period	43,712	145,299
Cash paid for interest
Cash paid for income taxes

Basis of Presentation _ Going C

Basis of Presentation – Going Concern Uncertainties	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation – Going Concern Uncertainties	Note 1. Basis of Presentation – Going Concern Uncertainties ProtoKinetix, Incorporated (the “Company”), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999. The Company is a medical research company whose mission is the advancement of human health care. The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins (“AFGP”) or anti-aging glycoproteins, trademarked AAGP. During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $ 30,000 10,000 6,000,000 25,000 The Company’s financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern. The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at September 30, 2022. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities. Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective. Management is presently engaged in seeking additional working capital through equity financing or related party loans. In addition, any significant disruption of global financial markets, reducing our ability to access capital, could negatively affect our liquidity and ability to continue operations. The exact impact is and will remain unknown and largely dependent upon future developments, including but not limited to information on the duration and spread of COVID-19, changes in customer demand, additional mitigation strategies proposed by governmental authorities (including federal, state, or local stay at home or similar orders), restrictions on the activities of our domestic and international suppliers and shipment of goods. The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K, filed March 10, 2022, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year. Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to valuation of equity related instruments issued, deferred income taxes, and the useful life and impairment of intangible assets. Cash Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time. Fair Value of Financial Instruments Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) Level 1 inputs are used to measure cash. At September 30, 2022, there were no other assets or liabilities subject to additional disclosure. Income Taxes The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled. Intangible assets – patent and patent application costs The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred. As at September 30, 2022, the Company does not hold any intangible assets with indefinite lives. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents. No amortization is recognized on patent application costs, as amortization of these costs will only commence once the patents have been granted. Research and Development Costs Research and development costs are expensed as incurred. Loss per Share and Potentially Dilutive Securities Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 94,690,000 84,690,000 14,800,000 11,855,429 Share-Based Compensation The Company has granted warrants and options to purchase shares of the Company’s common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model. The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance. Share-based compensation for non-employees in exchange for goods and services used or consumed in an entity’s own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period. Common stock Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty’s performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects. Related Party Transactions A related party is generally defined as (i) any person that holds 10% or more of the Company’s securities and their immediate families, (ii) the Company’s management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. Recent Accounting Pronouncements Certain new accounting pronouncements that have been issued are not expected to have a material effect on the Company’s financial statements.

Prepaid Expenses

Prepaid Expenses	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses	Note 3. Prepaid Expenses The following summarizes the Company’s prepaid expenses outstanding as at September 30, 2022 and December 31, 2021: Schedule of prepaid expenses September 30, December 31, Rental deposit $ 1,050 $ 1,050 Deposit on February 11, 2022, shareholder meeting — 24,945 Total Prepaid Expenses and Deposits $ 1,050 $ 25,995

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 4. Intangible Assets Intangible asset transactions are summarized as follows: Intangible asset transactions Patent Rights Patent Application Rights Total Cost Balance, December 31, 2020 $ 30,000 $ 261,186 $ 291,186 Additions — 90,985 90,985 Balance, December 31, 2021 $ 30,000 $ 352,171 $ 382,171 Additions — 74,556 74,556 Balance, September 30, 2022 $ 30,000 $ 426,727 $ 456,727 Accumulated amortization Balance, December 31, 2020 $ 16,500 $ — $ 16,500 Amortization 3,000 — 3,000 Balance, December 31, 2021 $ 19,500 $ — $ 19,500 Amortization 2,250 — 2,250 Balance, September 30, 2022 $ 21,750 $ — $ 21,750 Net carrying amounts December 31, 2021 $ 10,500 $ 352,171 $ 362,671 September 30, 2022 $ 8,250 $ 426,727 $ 434,977 During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the “Patent Assignment”) with the Institut National des Sciences Appliquees de Rouen (“INSA”) for the assignment of certain patents and all rights associated therewith (the “Patents”). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $ 30,000 2,250 2,250 During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the “Patent Application Rights”). In exchange for the Patent Application Rights, the Company agreed to pay $ 10,000 6,000,000 74,556 The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty. During the year ended December 31, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells” (the “New Patent Application Rights”). In exchange for the New Patent Application Rights, the Company agreed to pay $1 (paid). The Company incurred $ 2,415 No amortization was recorded on the Patent Application Rights to September 30, 2022.

Stock Options

Stock Options	9 Months Ended
	Sep. 30, 2022
Stock Options
Stock Options	Note 5. Stock Options Pursuant to an amendment on March 15, 2022, the aggregate number of shares that may be issued under the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”) is 97,700,000 shares, subject to adjustment as provided therein. The 2017 Plan is administered by the Company’s Board of Directors, or a committee appointed by the Board of Directors, and includes two types of options. Options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended, are referred to as incentive options. Options that are not intended to qualify as incentive options are referred to as non-qualified options. The exercise price of an option may be paid in cash, in shares of the Company's common stock or other property having a fair market value equal to the exercise price of the option, or in a combination of cash, shares, other securities and property. As of September 30, 2022, there are 94,690,000 Stock option transactions are summarized as follows: Schedule of Share-based Compensation, Stock Options, Activity Number of Stock Options Weighted Average Exercise Price Weighted Average Remaining Life $ (Years) Outstanding, December 31, 2020 82,650,000 0.15 Options cancelled (76,100,000 ) 0.16 Options exercised (750,000 ) 0.07 Options granted 78,890,000 0.11 Outstanding, September 30, 2021 84,690,000 0.13 4.23 Number of Stock Options Weighted Average Exercise Price Weighted Average Remaining Life $ (Years) Outstanding, December 31, 2021 84,690,000 0.15 Options granted 10,000,000 0.06 Outstanding, September 30, 2022 94,690,000 0.14 3.57 During the nine-month period ended September 30, 2022 the Company granted 10,000,000 Total share-based compensation for stock options granted during the period ended September 30, 2022 was $ 627,192 1,314,700 Schedule of weighted average assumptions September 30, 2022 September 30, 2021 Risk-free interest rate 1.76 % 1.76 % Dividend yield 0.00 % 0.00 % Expected stock price volatility 140.70 % 140.70 % Expected forfeiture rate 0.00 % 0.00 % Expected life 8 6 The following non-qualified stock options were outstanding and exercisable at September 30, 2022: Schedule of options by exercise price Expiry date Exercise Price Number of Options Number of $ December 31, 2022 0.06 800,000 800,000 August 31, 2023 0.08 600,000 600,000 November 8, 2023 0.09 4,000,000 4,000,000 May 5, 2026 0.11 150,000 150,000 October 25, 2026 0.10 500,000 500,000 November 26, 2026 0.10 250,000 250,000 August 3, 2028 0.11 78,390,000 78,390,000 March 14, 2030 0.06 10,000,000 7,500,000 94,690,000 92,190,000 As at September 30, 2022, the aggregate intrinsic value of the Company’s stock options is $ 0 2,107,500 0.06 0.09

Warrants

Warrants	9 Months Ended
	Sep. 30, 2022
Warrants
Warrants	Note 6. Warrants Warrant transactions for the nine-months ended September 30, 2022 are summarized as follows: Schedule of Stockholders' Equity Note, Warrants or Rights Number of Warrants Weighted Average Exercise Price $ Outstanding, December 31, 2021 12,081,143 0.19 Warrants expired (3,141,143 ) 0.07 Warrants expired (1,440,000 ) 0.10 Warrants granted 7,300,000 0.05 Outstanding, September 30, 2022 14,800,000 0.17 The following warrants were outstanding and exercisable as at September 30, 2022: Schedule of outstanding and exercisable Number of Warrants Exercise Price Expiry Date 6,000,000 $ 0.26 July 14, 2024 833,333 0.12 October 15, 2022 250,000 0.12 October 21, 2022 116,667 0.12 November 1, 2022 83,334 0.12 November 12, 2022 216,666 0.12 December 18, 2022 7,300,000 0.05 March 15, 2024 14,800,000

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders’ Equity	Note 7. Stockholders’ Equity The Company is authorized to issue 500,000,000 400,000,000 0.0000053 No During the nine-month period ended September 30, 2022, the Company: a) Issued 7,500,000 0.03 225,000 a) Issued 2,136,666 0.06 128,200 b) Issued 7,300,000 0.05 365,000 During the nine-month period ended September 30, 2021, the Company: a) Issued 3,528,572 0.07 247,001 b) Issued 200,000 24,000 c) Issued 1,440,000 0.10 144,000 d) Issued 3,000,000 0.12 260,000 e) Issued 555,556 750,000

Related Party Transactions and

Related Party Transactions and Balances	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions and Balances	Note 8. Related Party Transactions and Balances During the nine-month period ended September 30, 2022 and 2021, the Company entered into the following related party transactions: a) Pursuant to a consulting agreement with an effective date of November 14, 2017, a total of $ 45,000 45,000 9,450 9,450 b) On March 15, 2022, the Company granted 4,750,000 stock options to the Company’s CEO and 500,000 stock options to a Director of the Company, respectively. The 5,250,000 options granted have a term of 8 years and are exercisable at a price of $0.06 per share, expiring on March 14, 2030. No stock options were issued during the three-month period ending September 30, 2021. c) On March 15, 2022, the Company granted 1,500,000 stock options to the Company’s CFO. The options granted have a term of 8 years and are exercisable at a price of $0.06 per share, expiring on March 14, 2030. No stock options were issued during the three-month period ending September 30, 2021. d) The Company recognized $ 435,202 649,822l As at September 30, 2022 and December 31, 2021, there were $ 0

Commitments and Contingency

Commitments and Contingency	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingency	Note 9. Commitments and Contingency As at September 30, 2022, the Company has the following commitments: a) Entered into a consulting agreement with an effective date of January 1, 2017 whereby the Company would pay the consultant $ 7,000 b) Entered into a consulting agreement effective January 1, 2018, whereby the Company would pay the consultant $ 1,000 c) Entered into a consulting agreement effective April 1, 2019, whereby the Company would pay the consultant $ 1,500 Contingency The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, "Report of Foreign Bank and Financial Accounts" ("FBARs"). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs. Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no under reported tax liabilities. On November 30, 2017, the Company received a letter from the IRS concluding their review of the Company's tax returns under the program and accepting the returns as filed. No penalties have been assessed by the IRS to date, and management does not believe that the Company will incur any penalties relating to the tax years submitted under the program.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K, filed March 10, 2022, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Use of Estimates	Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to valuation of equity related instruments issued, deferred income taxes, and the useful life and impairment of intangible assets.
Cash	Cash Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) Level 1 inputs are used to measure cash. At September 30, 2022, there were no other assets or liabilities subject to additional disclosure.
Income Taxes	Income Taxes The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.
Intangible assets – patent and patent application costs	Intangible assets – patent and patent application costs The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred. As at September 30, 2022, the Company does not hold any intangible assets with indefinite lives. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents. No amortization is recognized on patent application costs, as amortization of these costs will only commence once the patents have been granted.
Research and Development Costs	Research and Development Costs Research and development costs are expensed as incurred.
Loss per Share and Potentially Dilutive Securities	Loss per Share and Potentially Dilutive Securities Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 94,690,000 84,690,000 14,800,000 11,855,429
Share-Based Compensation	Share-Based Compensation The Company has granted warrants and options to purchase shares of the Company’s common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model. The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance. Share-based compensation for non-employees in exchange for goods and services used or consumed in an entity’s own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.
Common stock	Common stock Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty’s performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.
Related Party Transactions	Related Party Transactions A related party is generally defined as (i) any person that holds 10% or more of the Company’s securities and their immediate families, (ii) the Company’s management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Certain new accounting pronouncements that have been issued are not expected to have a material effect on the Company’s financial statements.

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of prepaid expenses	Schedule of prepaid expenses September 30, December 31, Rental deposit $ 1,050 $ 1,050 Deposit on February 11, 2022, shareholder meeting — 24,945 Total Prepaid Expenses and Deposits $ 1,050 $ 25,995

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible asset transactions	Intangible asset transactions Patent Rights Patent Application Rights Total Cost Balance, December 31, 2020 $ 30,000 $ 261,186 $ 291,186 Additions — 90,985 90,985 Balance, December 31, 2021 $ 30,000 $ 352,171 $ 382,171 Additions — 74,556 74,556 Balance, September 30, 2022 $ 30,000 $ 426,727 $ 456,727 Accumulated amortization Balance, December 31, 2020 $ 16,500 $ — $ 16,500 Amortization 3,000 — 3,000 Balance, December 31, 2021 $ 19,500 $ — $ 19,500 Amortization 2,250 — 2,250 Balance, September 30, 2022 $ 21,750 $ — $ 21,750 Net carrying amounts December 31, 2021 $ 10,500 $ 352,171 $ 362,671 September 30, 2022 $ 8,250 $ 426,727 $ 434,977

Stock Options (Tables)

Stock Options (Tables)	9 Months Ended
	Sep. 30, 2022
Stock Options
Schedule of Share-based Compensation, Stock Options, Activity	Schedule of Share-based Compensation, Stock Options, Activity Number of Stock Options Weighted Average Exercise Price Weighted Average Remaining Life $ (Years) Outstanding, December 31, 2020 82,650,000 0.15 Options cancelled (76,100,000 ) 0.16 Options exercised (750,000 ) 0.07 Options granted 78,890,000 0.11 Outstanding, September 30, 2021 84,690,000 0.13 4.23 Number of Stock Options Weighted Average Exercise Price Weighted Average Remaining Life $ (Years) Outstanding, December 31, 2021 84,690,000 0.15 Options granted 10,000,000 0.06 Outstanding, September 30, 2022 94,690,000 0.14 3.57
Schedule of weighted average assumptions	Schedule of weighted average assumptions September 30, 2022 September 30, 2021 Risk-free interest rate 1.76 % 1.76 % Dividend yield 0.00 % 0.00 % Expected stock price volatility 140.70 % 140.70 % Expected forfeiture rate 0.00 % 0.00 % Expected life 8 6
Schedule of options by exercise price	Schedule of options by exercise price Expiry date Exercise Price Number of Options Number of $ December 31, 2022 0.06 800,000 800,000 August 31, 2023 0.08 600,000 600,000 November 8, 2023 0.09 4,000,000 4,000,000 May 5, 2026 0.11 150,000 150,000 October 25, 2026 0.10 500,000 500,000 November 26, 2026 0.10 250,000 250,000 August 3, 2028 0.11 78,390,000 78,390,000 March 14, 2030 0.06 10,000,000 7,500,000 94,690,000 92,190,000

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2022
Warrants
Schedule of Stockholders' Equity Note, Warrants or Rights	Schedule of Stockholders' Equity Note, Warrants or Rights Number of Warrants Weighted Average Exercise Price $ Outstanding, December 31, 2021 12,081,143 0.19 Warrants expired (3,141,143 ) 0.07 Warrants expired (1,440,000 ) 0.10 Warrants granted 7,300,000 0.05 Outstanding, September 30, 2022 14,800,000 0.17
Schedule of outstanding and exercisable	Schedule of outstanding and exercisable Number of Warrants Exercise Price Expiry Date 6,000,000 $ 0.26 July 14, 2024 833,333 0.12 October 15, 2022 250,000 0.12 October 21, 2022 116,667 0.12 November 1, 2022 83,334 0.12 November 12, 2022 216,666 0.12 December 18, 2022 7,300,000 0.05 March 15, 2024 14,800,000

Basis of Presentation _ Going_2

Basis of Presentation – Going Concern Uncertainties (Details Narrative)	12 Months Ended
	Dec. 31, 2015 USD ($) shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash consideration	$ 30,000
Additional patent applications	$ 10,000
Warrant issued | shares	6,000,000
Fair value adjustment of warrants	$ 25,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Antidilutive shares	14,800,000	11,855,429
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Antidilutive shares	94,690,000	84,690,000

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Rental deposit	$ 1,050	$ 1,050
Deposit on February 11, 2022, shareholder meeting		24,945
Total Prepaid Expenses and Deposits	$ 1,050	$ 25,995

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Beginning balance	$ 382,171	$ 291,186
Additions	74,556	90,985
Ending balance	456,727	382,171
Beginning balance	19,500	16,500
Amortization	2,250	3,000
Beginning balance	21,750	19,500
Ending balance	21,750	19,500
Net carrying amounts	434,977	362,671
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning balance	30,000	30,000
Additions
Ending balance	30,000	30,000
Beginning balance	19,500	16,500
Amortization	2,250	3,000
Beginning balance	21,750	19,500
Ending balance	21,750	19,500
Net carrying amounts	8,250	10,500
Patent Application Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning balance	352,171	261,186
Additions	74,556	90,985
Ending balance	426,727	352,171
Beginning balance
Amortization
Beginning balance
Ending balance
Net carrying amounts	$ 426,727	$ 352,171

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Intangible assets			$ 74,556	$ 66,981
Amortization of Intangible Assets	$ 750	$ 750	$ 2,250	$ 2,250
Additional patent applications						$ 10,000
Warrant issued						6,000,000
Grant Young [Member] | Technology Transfer Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Additional patent applications						$ 10,000
Warrant issued						6,000,000
Patent Application Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets						$ 30,000
Direct operating costs					$ 2,415

Stock Options (Details)

Stock Options (Details) - Equity Option [Member] - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding, beginning	84,690,000	82,650,000
Weighted average exercise price beginning balance	$ 0.15	$ 0.15
Options cancelled		(76,100,000)
Weighted Average Exercise Price, cancelled		$ 0.16
Options exercised		(750,000)
Weighted Average Exercise Price, exercised		$ 0.07
Option granted	10,000,000	78,890,000
Weighted Average Exercise Price, granted	$ 0.06	$ 0.11
Outstanding, ending	94,690,000	84,690,000
Weighed average exercise price ending balance	$ 0.14	$ 0.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	3 years 6 months 25 days	4 years 2 months 23 days

Stock Options (Details 1)

Stock Options (Details 1)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.76%	1.76%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0%	0%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	140.70%	140.70%
Expected forfeiture rate	0%	0%
Expected life	8 years	6 years

Stock Options (Details 2)

Stock Options (Details 2)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of outstanding	94,690,000
Number of options exercisable	92,190,000
Stock Option 1 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Dec. 31, 2022
Weighed average exercise price | $ / shares	$ 0.06
Number of outstanding	800,000
Number of options exercisable	800,000
Stock Option 2 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Aug. 31, 2023
Weighed average exercise price | $ / shares	$ 0.08
Number of outstanding	600,000
Number of options exercisable	600,000
Stock Option 3 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Nov. 08, 2023
Weighed average exercise price | $ / shares	$ 0.09
Number of outstanding	4,000,000
Number of options exercisable	4,000,000
Stock Option 4 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	May 05, 2026
Weighed average exercise price | $ / shares	$ 0.11
Number of outstanding	150,000
Number of options exercisable	150,000
Stock Option 5 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Oct. 25, 2026
Weighed average exercise price | $ / shares	$ 0.10
Number of outstanding	500,000
Number of options exercisable	500,000
Stock Option 6 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Nov. 26, 2026
Weighed average exercise price | $ / shares	$ 0.10
Number of outstanding	250,000
Number of options exercisable	250,000
Stock Option 7 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Aug. 03, 2028
Weighed average exercise price | $ / shares	$ 0.11
Number of outstanding	78,390,000
Number of options exercisable	78,390,000
Stock Option 8 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Mar. 14, 2030
Weighed average exercise price | $ / shares	$ 0.06
Number of outstanding	10,000,000
Number of options exercisable	7,500,000

Stock Options (Details Narrativ

Stock Options (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award options exercisable, number	92,190,000		92,190,000
Shares issued value share-based payment arrangement, after forfeiture	$ 143,486	$ 1,238,638	$ 627,192	$ 1,314,700
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$ 0		$ 0		$ 2,107,500
Weighted average fair value of stock options granted			$ 0.06	$ 0.09
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted	94,690,000		94,690,000
Share-based compensation arrangement by share-based payment award options exercisable, number	10,000,000		10,000,000

Warrants (Details)

Warrants (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrant outstanding, beginning | shares	12,081,143
Warrant weighted average exercise price, beginning | $ / shares	$ 0.19
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations | shares	(3,141,143)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | $ / shares	$ 0.07
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations | shares	(1,440,000)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | $ / shares	$ 0.10
Warrant granted | shares	7,300,000
Warrant weighted average exercise price, granted | $ / shares	$ 0.05
Warrant outstanding, ending | shares	14,800,000
Warrant weighted average exercise price, ending | $ / shares	$ 0.17

Warrants (Details 1)

Warrants (Details 1)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Class of Warrant or Right, Outstanding	14,800,000
Warrant 1 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Class of Warrant or Right, Outstanding	6,000,000
Warrant weighted average exercise price | $ / shares	$ 0.26
Expiry Date	July 14, 2024
Warrant 2 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Class of Warrant or Right, Outstanding	833,333
Warrant weighted average exercise price | $ / shares	$ 0.12
Expiry Date	October 15, 2022
Warrant 3 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Class of Warrant or Right, Outstanding	250,000
Warrant weighted average exercise price | $ / shares	$ 0.12
Expiry Date	October 21, 2022
Warrant 4 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Class of Warrant or Right, Outstanding	116,667
Warrant weighted average exercise price | $ / shares	$ 0.12
Expiry Date	November 1, 2022
Warrant 5 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Class of Warrant or Right, Outstanding	83,334
Warrant weighted average exercise price | $ / shares	$ 0.12
Expiry Date	November 12, 2022
Warrant 6 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Class of Warrant or Right, Outstanding	216,666
Warrant weighted average exercise price | $ / shares	$ 0.12
Expiry Date	December 18, 2022
Warrant 7 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Class of Warrant or Right, Outstanding	7,300,000
Warrant weighted average exercise price | $ / shares	$ 0.05
Expiry Date	March 15, 2024

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Shares authorized	500,000,000		400,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0000053		$ 0.0000053
Dividends declared	$ 0		$ 0
Number of shares issued		555,556
Warrant [Member]
Defined Benefit Plan Disclosure [Line Items]
Warrants exercised		200,000
Total proceeds		$ 24,000
Equity Option [Member]
Defined Benefit Plan Disclosure [Line Items]
Option exercised		750,000
Investors [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares issued	7,500,000
Share Price	$ 0.03
Stock Issued During Period, Value, New Issues	$ 225,000
Investors One [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares issued	2,136,666
Share Price	$ 0.06
Stock Issued During Period, Value, New Issues	$ 128,200
Investors Two [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares issued	7,300,000
Share Price	$ 0.05
Stock Issued During Period, Value, New Issues	$ 365,000
Investors Three [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares issued		3,528,572
Share Price		$ 0.07
Stock Issued During Period, Value, New Issues		$ 247,001
Investors Four [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares issued		1,440,000
Share Price		$ 0.10
Stock Issued During Period, Value, New Issues		$ 144,000
Investors Five [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares issued		3,000,000
Share Price		$ 0.12
Stock Issued During Period, Value, New Issues		$ 260,000

Related Party Transactions an_2

Related Party Transactions and Balances (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction	$ 45,000	$ 45,000
Share-based payment arrangement, expense, after tax	435,202	649,822
Owing to related parties	0		$ 0
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Increase (Decrease) in Due from Officers and Stockholders, Current	$ 9,450	$ 9,450

Commitments and Contingency (De

Commitments and Contingency (Details Narrative) - USD ($)				3 Months Ended		9 Months Ended
	Apr. 02, 2019	Jan. 02, 2018	Jan. 02, 2017	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Defined Benefit Plan Disclosure [Line Items]
Research and development expense				$ 160,994	$ 100,888	$ 426,968	$ 250,419
Consultant [Member]
Defined Benefit Plan Disclosure [Line Items]
Research and development expense			$ 7,000
Marketing expense		$ 1,000
Travel and entertainment expense	$ 1,500